Anavex Life Sciences logo
Anavex Life Sciences
AVXL | NASDAQ
Chart Builder DCF Calculator
$0.82
-$0.11 (-12.16%)
At close: Nov 16, 2026, 4:00 PM ET
$0.85
+$0.03 (+3.66%)
After-hours: Nov 16, 2026, 7:30 PM ET

Anavex Life Sciences Company Profile

Company profile explained

Company Profile

Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.

Key Executives

Name Position
Terrie Kellmeyer Interim Chief Executive Officer
Sandra Boenisch Principal Financial Officer & Treasurer

Latest SEC Filings

Date Type Title
Oct 20, 2026 8-K Current Report
Oct 15, 2026 8-K Current Report
Oct 05, 2026 3 Filing
Oct 05, 2026 3 Filing
Sep 28, 2026 4 Filing
Sep 28, 2026 8-K Current Report
Sep 21, 2026 DFAN14A Filing
Sep 18, 2026 DFAN14A Filing
Sep 17, 2026 DFAN14A Filing
Sep 15, 2026 DEFA14A Filing
View All SEC Filings ➞
Anavex Life Sciences
Anavex Life Sciences logo
Country United States
IPO Date Aug 2, 2006
Industry Biotechnology
Sector Healthcare
Employees 34
CEO Terrie Kellmeyer

Contact Details

630 5th Avenue New York City, New York 10111 United States

Stock Details

Ticker Symbol AVXL
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001314052
CUSIP Number 032797300
ISIN Number US0327973006
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.